Cocrystal Pharma (NASDAQ:COCP) (NASDAQ: COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing a structure-based drug design platform, Cocrystal aims to identify small molecule inhibitors that target essential viral proteins across a broad range of human pathogens. The company’s proprietary platform integrates advanced computational chemistry, protein crystallography, and biophysical screening to accelerate the progression of drug candidates from discovery through clinical evaluation.
Cocrystal’s pipeline includes multiple programs directed against high-priority viral targets such as coronaviruses, influenza viruses, hepatitis C virus and norovirus. The company has advanced lead compounds into preclinical and clinical stages, with certain candidates designed to inhibit viral replication by binding to key enzymes critical for viral lifecycle. In addition to internal discovery efforts, Cocrystal collaborates with academic institutions, contract research organizations and government agencies to leverage external expertise and expand its antiviral portfolio.
Founded in 2010 and headquartered in Bothell, Washington, Cocrystal Pharma operates discovery laboratories in Rochester, New York and maintains partnerships spanning North America and Europe. The company’s global approach addresses both emerging and endemic viral threats, positioning its pipeline to meet unmet medical needs in infectious disease. Regulatory interactions to date have included pre-IND discussions with the U.S. Food and Drug Administration, supporting the advancement of clinical candidates.
Under the leadership of President and Chief Executive Officer Kenneth L. Regan, Cocrystal is guided by an experienced management team with backgrounds in virology, medicinal chemistry and pharmaceutical development. The executive team’s collective expertise in antiviral drug discovery and commercialization strategies underpins the company’s mission to deliver safe and effective therapies for patients affected by serious viral infections worldwide.
